Home | Terms of Use | Privacy Statement | Contact Us For U.S. healthcare professionals only.
		Clinical Practice Guidelines   Video Watch a Biological  Video online...   Clinical practice guidelines were developed by a panel of experts from the Mucositis Study Section of the MASCC and the International Society for Oral Oncology (ISOO). Evidence-based clinical practice guidelines were produced in 2004 based on a review of literature published between January 1966 and May 2002. The evidence-based clinical practice guidelines are presented as a bench-mark for clinicians to use for routine care of appropriate patients. The panel expects to review the guidelines annually and reconvene every 3 years to update the guidelines.1 Recommendations were created from higher levels of evidence and suggestions were made when evidence was of a lower level and there was a consensus regarding the interpretation of evidence by the panel. The guideline committee determined there was insufficient evidence to support a guideline for many products including the use of amifostine, azelastine, chlorhexidine and clarithromycin to prevent oral mucositis. The guidelines panel suggest oral care protocols and education of patients should be used in an attempt to reduce severity of oral mucositis.1 For prevention of oral mucositis in patients with hematologic malignancies receiving high-dose chemotherapy with or without total-body irradiation (TBI) plus hematopoietic stem cell transplant (HSCT), the panel1: Recommends that in centers capable of supporting the necessary technology and training, low-level laser therapy is used to reduce incidence of oral mucositis and associated pain in patients receiving high-dose chemotherapy or chemotherapy + radiotherapy before HSCT. For basic care for patients undergoing HSCT, the panel1: Recommends patient-controlled analgesia with intravenous morphine as the treatment of choice for oral mucositis pain in patients having HSCT. 1 Rubenstein EB, et al. Cancer. 2004;100(suppl 9):2026-2046. Back to top ABOUT ORAL MUCOSITIS ABOUT KEPIVANCE® TOOLS AND RESOURCES FOR NURSES FOR PHARMACISTS IMPORTANT PRODUCT SAFETY INFORMATION
	Kepivance® is indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support. The safety and efficacy of Kepivance® have not been established in patients with non-hematologic malignancies. Important Safety Information In patients with hematologic malignancies, the most common serious adverse reaction in clinical trials attributed to Kepivance® was skin rash reported in less than 1% of patients.   Contact | Reimbursement | Biovitrum.com | Site Map Prescribing Information © 2008 Biovitrum AB (publ). All rights reserved.